Anaphore, Inc Receives $8M Financing.SAN DIEGO San Diego (săn dēā`gō), city (1990 pop. 1,110,549), seat of San Diego co., S Calif., on San Diego Bay; inc. 1850. San Diego includes the unincorporated communities of La Jolla and Spring Valley. Coronado is across the bay. -- Anaphore Inc, a newly-formed protein therapeutics company located in San Diego, California “San Diego” redirects here. For other uses, see San Diego (disambiguation). San Diego is a coastal Southern California city located in the southwestern corner of the continental United States. As of 2006, the city has a population of 1,256,951. , today announced an $8 Million financing round from 5AM Ventures and Versant Ventures. Richard Ulevitch Richard Ulevitch, is Chairman of the Department of Immunology at The Scripps Research Institute. Ulevitch has an AB from Washington and Jefferson College and a PhD in Biochemistry from the University of Pennsylvania. , Ph.D., a Venture Partner with 5AM Ventures, co-founder of Anaphore and former Chairman of the Department of Immunology immunology, branch of medicine that studies the response of organisms to foreign substances, e.g., viruses, bacteria, and bacterial toxins (see immunity). Immunologists study the tissues and organs of the immune system (bone marrow, spleen, tonsils, thymus, lymphatic of the Scripps Research Institute, stated, "The 5AM Ventures investment represents our belief in the significant advancements occurring in the treatment of immune-based diseases and protein therapeutics broadly." Anaphore was created through the acquisition of Borean Pharma ApS, a Danish biotechnology company with both a product portfolio and technology platforms for creating improved protein therapeutics. The Danish firm spent six years establishing the technologies and therapeutic pipeline that provides the strong foundation for Anaphore. Anaphore offers technology collaborations in all therapeutic areas. Katherine Bowdish, Ph.D., a leader in protein therapeutic technologies, former President of Alexion Antibody Technologies, and Senior Vice President of Alexion Pharmaceuticals has joined as CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . Dr. Bowdish described the platforms as "fundamental improvements in protein biologics that will be used to create new medicines with significant advantages in affinity, selectivity selectivity /se·lec·tiv·i·ty/ (se-lek-tiv´i-te) in pharmacology, the degree to which a dose of a drug produces the desired effect in relation to adverse effects. selectivity 1. and pharmaceutical properties." Anaphore's internal product development opportunities will initially focus on immune-based diseases. In addition to Drs. Bowdish and Ulevitch, Anaphore's Board of Directors includes Andy Schwab (Managing Partner, 5AM Ventures), Brad Bolzon, Ph.D., (Managing Director, Versant Ventures), Phyllis Whiteley, Ph.D., (co-founder of Anaphore) and Steve Kaldor, Ph.D., (President & CEO of Ambrx, Inc.). For more information about the company, visit www.anaphoreinc.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion